Premium
Infliximab treatment for steroid‐refractory acute graft‐versus‐host disease after orthotopic liver transplantation: A case report
Author(s) -
Piton Gaël,
Larosa Fabrice,
Minello Anne,
Becker MarieClaude,
Mantion Georges,
Aubin François,
Deconinck Eric,
Hillon Patrick,
Di Martino Vincent
Publication year - 2009
Publication title -
liver transplantation
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.814
H-Index - 150
eISSN - 1527-6473
pISSN - 1527-6465
DOI - 10.1002/lt.21793
Subject(s) - medicine , infliximab , hematopoietic stem cell transplantation , liver transplantation , refractory (planetary science) , transplantation , graft versus host disease , immunology , tumor necrosis factor alpha , disease , gastroenterology , physics , astrobiology
Acute graft‐versus‐host disease (GVHD) following orthotopic liver transplantation is a rare but severe disease with a 75% death rate in adults. Various therapeutic strategies have been proposed for steroid‐refractory GVHD, but there is still no consensus. Tumor necrosis factor‐alpha is a key inflammatory cytokine involved in acute GVHD physiopathology, and infliximab has shown encouraging results for the treatment of acute GVHD following hematopoietic stem cell transplantation. We report the first case of acute GVHD following liver transplantation that was refractory to steroids and anti‐lymphocyte globulin but was successfully treated with infliximab. Liver Transpl 15:682–685, 2009. © 2009 AASLD.